0.33
Pavmed Inc Aktie (PAVM) Neueste Nachrichten
Ascendiant Capital Maintains PAVmed (PAVM) Buy Recommendation - Nasdaq
Ascendiant Capital Lowers Price Target for PAVmed (PAVM) to $17. - GuruFocus
PAVmed stock price target lowered to $17 from $20 at Ascendiant Capital - Investing.com
Lucid Diagnostics reports real-world data on esophageal test device By Investing.com - Investing.com Nigeria
Lucid Diagnostics (Nasdaq: LUCD) reports 95% EsoCheck success in 11,991 patients - Stock Titan
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection - Sahm
PAVmed Approves Reverse Stock Split Amendment - TipRanks
Lucid Diagnostics Announces $15.3 Million Registered Direct Offe - GuruFocus
Can PAVmed Inc. stock rebound after recent weaknessMarket Growth Report & Daily Market Momentum Tracking - Newser
Is PAVmed Inc. stock cheap compared to fundamentals2025 Short Interest & Capital Efficiency Focused Ideas - Newser
PAVmed (PAVM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
What drives PAVmed Inc stock priceInflation Impact on Stocks & Control Your Emotions With Discipline Tools - earlytimes.in
Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30% - Yahoo Finance Singapore
Risk Check: Will PAVmed Inc. stock gain from strong economyRecession Risk & Advanced Swing Trade Entry Plans - BỘ NỘI VỤ
Is PAVmed Inc. stock a buy on dipsPortfolio Growth Summary & Capital Protection Trade Alerts - moha.gov.vn
Why Being Public Gave PavMed a Competitive Edge - Medical Device and Diagnostic industry
What analysts say about PAVmed Inc stockPrice Channel Trading & Small Investment Capital Tips - earlytimes.in
Pavmed Inc. Reports Q3 2025 Earnings and Strategic Focus - MSN
Will PAVmed Inc. stock benefit from upcoming earnings reports2025 Retail Activity & Low Drawdown Investment Strategies - newser.com
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree - PR Newswire
Will PAVmed Inc. stock deliver strong dividend growthStop Loss & Weekly Top Stock Performers List - newser.com
GenomeWeb Names Lucid Diagnostics (Nasdaq: LUCD) 2025 Best Places to Work Honoree - Stock Titan
Is PAVmed Inc. stock ready for breakoutPortfolio Gains Report & Community Driven Trade Alerts - newser.com
Is PAVmed Inc. stock cheap at current valuationJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Combining machine learning predictions for PAVmed Inc.July 2025 Analyst Calls & Daily Technical Stock Forecast Reports - newser.com
Why retail investors pile into PAVmed Inc. stock2025 Top Gainers & High Yield Stock Recommendations - newser.com
Should I hold or sell PAVmed Inc. stock in 20252025 Stock Rankings & Community Trade Idea Sharing Platform - newser.com
PAVmed Inc. (NASDAQ:PAVM) Q3 2025 Earnings Call Transcript - MSN
Is PAVmed (NASDAQ:PAVM) Using Debt Sensibly? - simplywall.st
PAVmed Inc. (PAVMW) AI-Powered Stock Analysis - Meyka
Candlestick signals on PAVmed Inc. stock today2025 Investor Takeaways & Real-Time Chart Breakout Alerts - newser.com
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Detecting support and resistance levels for PAVmed Inc.Market Growth Summary & Weekly Top Gainers Trade List - newser.com
PAVmed Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:PAVM) 2025-11-14 - Seeking Alpha
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - Eastern Progress
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):